Facts and controversies in mixed connective tissue disease
Med Clin (Barc). 2018 Jan 12;150(1):26-32.
doi: 10.1016/j.medcli.2017.06.066.
Epub 2017 Aug 31.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, España; Instituto de Investigación Biomédica Hospital Gregorio Marañón, Madrid, España; Universidad Complutense de Madrid, Madrid, España. Electronic address: juliamartinezbarrio@gmail.com.
- 2 Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, España; Instituto de Investigación Biomédica Hospital Gregorio Marañón, Madrid, España.
- 3 Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, España; Instituto de Investigación Biomédica Hospital Gregorio Marañón, Madrid, España; Universidad Complutense de Madrid, Madrid, España.
Abstract
Mixed connective tissue disease (MCTD) is a systemic autoimmune rheumatic disease (SARD) characterised by the combination of clinical manifestations of systemic lupus erythematosus (SLE), cutaneous systemic sclerosis (SSc) and polymyositis-dermatomyositis, in the presence of elevated titers of anti-U1-RNP antibodies. Main symptoms of the disease are polyarthritis, hand oedema, Raynaud's phenomenon, sclerodactyly, myositis and oesophageal hypomobility. Although widely discussed, most authors today accept MCTD as an independent entity. Others, however, suggest that these patients may belong to subgroups or early stages of certain definite connective diseases, such as SLE or SSc, or are, in fact, SARD overlap syndromes.
Keywords:
Anti-U1-RNP; Enfermedad mixta del tejido conectivo; Mixed connective tissue disease; Seronegative; Seronegativo.
Copyright © 2017 Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Diagnosis, Differential
-
Dissent and Disputes
-
Humans
-
Mixed Connective Tissue Disease / diagnosis*
-
Mixed Connective Tissue Disease / mortality
-
Mixed Connective Tissue Disease / therapy